High expression of BAALC in cytogenetically normal-acute myeloid leukemia (AML) patients is associated with primary resistant disease, shorter relapse-free, disease-free and overall survival. [1] [2] [3] [4] However, there is no published data evaluating the role of BAALC in the hematopoietic system. BAALC is located on human chromosome 8q22.3 and is highly conserved in mammals. High BAALC expression levels were first identified in a study of AML patients with trisomy 8 as a sole abnormality, 5 and was shown to correlate highly with MN1 expression, 6, 7 a potent oncogene in leukemogenesis. 8 Several isoforms of BAALC have been described with isoform 2 (also known as 1-6-8) being the most abundant in the brain and in AML samples. 5 Using retroviral gene transfer, bone marrow (BM) transplantation and expression analysis of BAALC and MN1 in cytogenetically normal AML patients, we evaluated the role of BAALC in hematopoiesis. Details of materials and methods can be found in the Supplementary information. In total, 140 newly diagnosed adult AML patients with cytogenetically normal AML were evaluated by real-time RT-PCR for BAALC and compared with MN1 transcript expression.
2,3 BAALC expression was found to correlate highly with MN1 expression (R ¼ 0.71, Pearson's correlation, Figure 1a ).
This finding stimulated us to further investigate whether BAALC was upregulated as a consequence of MN1 upregulation or vice versa. Retroviral overexpression of human full-length MN1 in a murine model system induces rapid-onset AML. 8, 9 We used murine BM cell lines immortalized by retroviral expression of Hoxa9 or NUP98HOXD13, and co-transduced these cells with full-length MN1 or a control vector as described before. Table S1 for primer sequences). Thus, it appears unlikely that MN1 and/or BAALC cross-regulate each other. Rather, dysregulation of a common upstream regulatory mechanism may be responsible for the observed coordinated upregulation in human AML cells.
We next evaluated the effect of BAALC on myeloid differentiation and stem cell self-renewal. Full-length BAALC (isoform 2) was retrovirally expressed in murine BM cells and in BM cell lines immortalized by HoxA9 or NUP98HOXD13 using a retroviral vector system. High-level expression of BAALC was confirmed by quantitative RT-PCR using a human primer/probe set.
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In BAALC-transduced HoxA9-and NUP98HOXD13-expressing cell lines, the threshold cycle for human BAALC expression was 15.9 and 15.5, respectively, whereas BAALC was undetectable in the non-transduced cell lines, demonstrating high expression levels of BAALC.
First, we evaluated 5-fluorouracil-treated murine BM cells transduced with BAALC in vitro. These cells were not immortalized when cultured in media supplemented with interleukin-3, stem cell factor and interleukin-6 (data not shown), and they did not show sustained colony-forming cell activity (Supplementary Figure S1) . Only very small colonies were noted after the fourth plating and no colonies were noted thereafter. When BM cells were transduced with HoxA9 with or without BAALC, these cells grew as immortalized cell lines that produced large colonies and could easily be replated beyond the fourth replating (Supplementary Figure S1A and data not shown). Transplantation of BM cells that were transduced with BAALC and kept in culture for 5 (n ¼ 3), 7 (n ¼ 3) or 17 (n ¼ 3) days after transduction resulted in negligible engraftment of 1±1% at 4 weeks after transplantation and disappeared thereafter (data not shown). We next evaluated whether BAALC may cooperate with other myeloid oncogenes. Bone marrow cells were transduced with FLT3-ITD or AML1-ETO and either a control vector or BAALC. The colony-forming potential of FLT3-ITD cells with or without BAALC was limited to the first plating (Supplementary Figure S1B) . Expression of AML1-ETO in BM cells enhanced colony formation up to the fifth replating. Co-transduction of BAALC with AML1-ETO reduced the total colony-forming cells output from third to fifth replating (Supplementary Figure S1B) . These experiments underscore that BAALC does not enhance self-renewal or proliferation of hematopoietic progenitor cells.
We next evaluated its effect on all-trans retinoic acid (ATRA)-induced differentiation and proliferation arrest. Cell lines derived from NUP98HOXD13-transduced BM are very sensitive to ATRA-induced proliferation arrest and differentiation Letters to the Editor induction. Interestingly, co-transduction of BAALC increased the 50% inhibitory concentration of ATRA in NUP98HOXD13 cells (Po0.05), although to a lower magnitude than MN1, a known inhibitor of ATRA-induced differentiation (4.3-fold versus 30-fold, respectively; Figure 2a) . Expression of retinoic acid receptor target genes was assessed in NUP98HOXD13 cells that expressed a control vector, BAALC or MN1, and that were treated with or without 1 mM ATRA. Similarly to MN1 cells, ATRA-treated BAALC cells expressed significantly lower levels of retinoic acid receptor target genes Cebpa, Pu.1 and p21 compared with control cells (Figure 2b , see Supplementary  Table S1 for primer sequences), supporting its differentiationinhibiting effect. Future studies are required to clarify the mechanism how BAALC interferes with transcriptional control of these transcription factors.
To test whether the differentiation-inhibiting effect had a role in leukemia development, we combined BAALC with Hoxa9. Hoxa9 is a well-established stimulator of stem cell self-renewal that induces a myeloproliferative neoplasia with long latency, whereas myeloid differentiation is only partially blocked. 12 5-Fluorouracil-treated BM cells transduced with HoxA9 and either BAALC or a control vector were transplanted into lethally irradiated mice and were monitored for engraftment and hematopoietic lineage distribution. All of these mice maintained stable engraftment of green fluorescence protein-positive cells. After a period with low engraftment, a rapid increase in engraftment was observed (data not shown). Between 113 and 196 days post-transplantation (median 139.5 days), mice had to be killed because of disease symptoms that were characterized by impaired movement, pallor and, in some instances, massive swelling of cervical or axillary lymph nodes (survival analysis in Figure 2c ). Upon examination, sick mice showed leukocytosis (more than 8 Â 10 4 WBC/ml), massively enlarged spleens (up to 1.02 g), anemia (mean hemoglobin of 11.3 g/dl, n ¼ 5; lowest hemoglobin 6.3 g/dl) and thrombocytopenia (mean 73 Â 10 Figure S2) . To analyze the clonal composition of leukemias resulting from HoxA9 þ BAALC-transduced cells, we carried out proviral integration analysis by Southern blot using a green fluorescence protein probe to detect the BAALC provirus. One to two BAALC viral integrations were detected in each mouse in BM and spleen, consistent with clonal disease (Supplementary Figure S3) . From five analyzed mice, we found three different integration patterns, suggesting that clonal selection had occurred before and after transplantation. This finding underscores that BAALC was critical for leukemic transformation, and that additional mutations had to be acquired for the development of full-blown leukemia.
Although formally we cannot rule out insertional mutagenesis, several lines of evidence suggest that BAALC was involved in the development of the observed leukemias: First, our experiment was well controlled by transplantation of Hoxa9 þ CTL-transduced cells that did not develop leukemias during the observation time. Second, mice were transplanted with cells from two independent transductions of primary BM cells with identical results. Third, by Southern blot analysis we found leukemias derived from several different clones (the analyzed mice received cells from the same initial transduction), suggesting that BAALC expression rather than a specific insertion site with consecutive oncogene activation or tumor suppressor gene inactivation was a prerequisite for leukemic outgrowth. However, the fact that the disease was monoclonal or at most biclonal, and that leukemias in secondary transplantations had a shorter latency than in primary animals suggest that additional mutations occurred in BAALC þ Hoxa9-transduced cells, giving certain clones a proliferative advantage in vivo. As no cooperative effect of BAALC was observed with other myeloid oncogenes tested, the leukemia-accelerating effect in Hoxa9 cells and the differentiation-blocking effect in NUP98HOXD13 cells may be specific to HOX-transformed cells.
Our study evaluated the functional role of BAALC in leukemogenesis. Although constitutive activation of BAALC did not promote proliferation or survival of hematopoietic stem or progenitor cells, we found evidence that BAALC blocks myeloid differentiation and thus promote leukemogenesis when combined with the self-renewal promoting oncogene HoxA9. Additional studies are required to delineate the molecular mechanism of BAALC and its role as an antileukemic target.
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